Cancer/testis antigen 1 (127-136)

Cancer/testis antigen 1 (127-136) is a synthetic peptide fragment derived from the well-characterized cancer/testis antigen family, specifically representing amino acid residues 127 to 136 of the parent protein. As a member of the cancer/testis antigen group, this peptide is notable for its restricted expression in normal adult tissues and prevalent upregulation in various malignancies, making it a valuable molecular tool in oncology and immunology research. Its well-defined sequence and immunogenic properties have positioned it as a critical reagent in studies exploring tumor-associated antigens, T cell recognition, and antigen presentation. The biochemical specificity and relevance of this peptide support its widespread use in fundamental and translational research settings.

Epitope mapping: The 127-136 peptide fragment serves as a precise epitope for characterizing T cell responses against cancer/testis antigens. Researchers utilize it in assays such as ELISPOT, intracellular cytokine staining, and tetramer analysis to delineate the specificity and magnitude of CD8+ cytotoxic T lymphocyte responses. This application is essential for understanding the immunogenic landscape of tumor antigens, dissecting mechanisms of immune recognition, and identifying potential targets for immunotherapeutic interventions.

Immunogenicity assessment: The peptide is frequently employed in in vitro stimulation assays to evaluate the immunogenic potential of cancer/testis antigens. By exposing peripheral blood mononuclear cells or tumor-infiltrating lymphocytes to the peptide, investigators can assess activation markers, cytokine production, and proliferation. These studies inform the design of antigen-specific vaccines and provide insights into the natural immune repertoire capable of recognizing tumor-associated epitopes.

Antigen presentation studies: The defined sequence of this peptide enables its use in examining the molecular mechanisms of antigen processing and presentation via major histocompatibility complex (MHC) class I molecules. By loading the peptide onto antigen-presenting cells, researchers can investigate the efficiency of peptide-MHC binding, the stability of peptide complexes, and the downstream activation of T cells. Such studies are fundamental for optimizing antigen delivery strategies and understanding immune evasion by tumors.

Peptide-based screening: Laboratories employ the 127-136 peptide in high-throughput screening platforms to identify and validate T cell receptors (TCRs) or monoclonal antibodies with specificity for cancer/testis antigens. This approach accelerates the discovery of novel immunotherapeutic candidates and supports the engineering of TCRs or antibody-based modalities with enhanced specificity and affinity for tumor-associated epitopes.

Functional analysis of immune modulation: The peptide is also utilized in functional assays to investigate the regulatory mechanisms that influence anti-tumor immune responses. By incorporating it into co-culture systems or immune checkpoint studies, scientists can probe the effects of immune modulators, such as checkpoint inhibitors or cytokines, on antigen-specific T cell activity. These experiments contribute to a deeper understanding of how the tumor microenvironment shapes immune surveillance and response to immunotherapies.

1. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

2. Quantitative Analysis of Ligands Effects on Bioefficacy of Nanoemulsion encapsulating Depigmenting Active

3. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

4. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

5. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features